For most of their lives, Upper Hutt brothers Alec and Ronan Gall have used the blue Vento-lin inhalers familiar to several generations of New Zealanders to relieve their asthma symptoms.
But over the past year, Alec, 14, and Ronan, 11, have been using a different inhaler, Symbicort, which both relieves and helps prevent the symptoms. Symbicort is now the recommended first-line treatment to relieve symptoms in adolescents and adults after clinical trials by the Medical Research Institute of New Zealand (MRINZ) found it reduced the incidence of severe asthma attacks by between a third and a half.
Under current asthma guidelines, Symbicort is not yet recommended for children with mild asthma who, as with adults, account for most asthma cases. Instead, their recommended treatment is Ventolin or a similar inhaler called Respigen. However, that may eventually change, thanks to the efforts of Alec, Ronan and another 378 young people aged 5 to 15 taking part in an MRINZ clinical trial comparing the effectiveness of Ventolin and Symbicort in children with mild asthma.
The Children’s Anti-inflammatory Reliever (CARE) study has already recruited more than 200 participants and has now started recruiting in Auckland. Each participant is randomly assigned to use either a Ventolin or a Symbicort inhaler for a year whenever they have asthma symptoms. During the study, researchers meet with the participants five times (three times in person and twice remotely) to check how they’re going.
“It’s quite easy and not at all onerous,” says the boys’ mother, Louise Gall. “In terms of the paperwork, it’s just really noting down if the kids have had doctors’ appointments and what they’ve had the appointments for.”
FINANCIAL TOLL
This story is from the November 05, 2022 edition of New Zealand Listener.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the November 05, 2022 edition of New Zealand Listener.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
The rest is history
Rest - both sleep and non-sleep - is essential to help our overstressed bodies and minds repair themselves. But many of us remain in a constant state of 'fight, flight or freeze'.
Right and power
Israel is profiting financially and extending its global technological influence in response to the October 7 massacre, says investigative journalist Antony Loewenstein.
Dolphins be damned
Is SailGP's future in this country really under threat because of an at-risk marine mammal?
Orwellian irony
Our thinking about one of the 20th century's best-known writers is being challenged by the 'smelly little truths' Anna Funder uncovered about George Orwell's marriage.
The alchemist
Talent and a little magic have taken state-house kid Moses Mackay to the heights of Italian opera. He's coming back to sprinkle some of his gold dust around.
Good Lord, he was scandalous
Lord Byron still fascinates 200 years after his death, but more for his bohemian lifestyle than his poetry.
Stars in their eyes
Debut novel a heady mix of grief, astronomy and love.
Dark matter
Ngaio Marsh-style whodunnit set among academia attached to the Mt John Observatory.
Mirren's mirror on Meir
Dame Helen talks about playing Golda Meir, Israel's iron lady, during a pivotal chapter in the controversial politician's long career.
Game, set and match
Love, sex and great tennis take centre court in this highly charged drama.